Search

Displaying results 861 - 870 of 10000 in total
  1. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells.

  2. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Chinese hamster ovary cell line [FDA Label]. … In particular, while human thrombin products are made from pooled human source plasma, recombinant thrombin is a human coagulation protein produced via recombinant DNA technology from a genetically modified

  3. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    The use of this compound has been shown to effectively reduce prion levels in an in vitro inactivation assay [A32334]. … Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru).

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% ECategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.

    Mixtures: Troxyca ER, Troxyca ERCategories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive Disorders
  5. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    Ergocalciferol is an inactivated vitamin D analog.[A177526] It is synthesized by some plants in the presence of UVB light. … Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.

    Mixtures: Formula EC, Vitamines Pour Bebes Et Enfants
  6. Drug

    Sulfamethoxazole

    go.drugbank.com/drugs/DB01015
    ApprovedInvestigational

    in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps

    Mixtures: COTRIM E RATIO 480MG/5ML, EUSAPRIM E SUSPENS F ERWSynonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
  7. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant].

  8. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line

  9. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSSynonyms: (E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine, trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene
  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.